Wait a second!
More handpicked essays just for you.
More handpicked essays just for you.
Ethical issues within the pharmaceutical industry
Ethical issues in pharmaceuticals
Ethics in pharmacy
Don’t take our word for it - see why 10 million students trust us with their essay needs.
Recommended: Ethical issues within the pharmaceutical industry
Investment Tactics Comparison: Dimension Therapeutics and Voyager Therapeutics use very similar investor relations tactics. Both use distinct investor relations links with up to date stock info, investor event calendars, and annual financial reports. Each company’s website also provides detailed research programs including their stage of development. It is very difficult to ascertain either company’s ethics and profitability potential from this generic form of information. Only noticeable difference is dimension offers an investment calculator, and more frequent updates on press releases. You have to look beyond the investor page to get a full view of which provides the best investment portfolio. The numbers only tell part of the story which would indicate Voyager as the best option. However, Voyager’s site is very impersonal completely lacking any connection to employee and community relations. Unless familiar with Voyager Therapeutics you would walk away with little understanding about their identity. Dimension on the other hand provides a brief cultural background for interested job seekers and detailed community links. You can visit several leading foundations sponsoring their research. These sites in turn give you a better understanding of the disease and the ability to contribute to a cure. These links by far give Dimension a more personable feel over Voyager. Another strong case for Dimension is a recent press release indicating the large expansion of their research labs. This provides a view of their intended direction given their funding from their initial public offering. Where Voyager stock prices may be peeking, Dimension’s expansion could offer a higher financial yield. With stronger employee and community relations, a more detailed …show more content…
Proven Maxims:
“Participation in, or awareness of, the decision process increases the likelihood of acceptance”
• Dimension’s higher detail into programs and course of action with investor funds give this maxim
In 2014 DaVita’s return on investment (ROI) ranked third highest in the industry (“DaVita 's ROI”, n.d.). The organization reported an average ROI of 4.96%, ROI has increased since 2012 (“DaVita 's ROI”, n.d.). Market share is a way to evaluate the portion of an industry held by an organization, a measure of performance relative to the competition (“Market share”, n.d.). In 2014 DaVita held a third of the global market share while their biggest competitor, Fresenius, had a five percent lead in market share. Experts believe DaVita has no reason to worry their shares “over the past year, DaVita has a 10% lead on Fresenius and that lead only increases at the two-year (roughly 60%), and five-year
In deciding whether to invest in Deltex, we have to consider some advantages and disadvantages of this deal first.
Threat of new entrants is relatively high. Companies forming alliances are potential rivals. Even if earlier such company was not considered to be a threat, after merging with some research and development company or forming alliance with another pharmaceutical company it would become a rival to Eli Lilly. The threat is however weakened by significant research and development costs necessary to successfully enter the business. Eli Lilly’s focus on a relatively narrow market of sedatives and antidepressants weakens the threat of new entrants, but other products that form lesser part of company’s sales such as insulin and others are exposed to high threat of new entrants. The need of obtaining certificates and licenses also weakens the threat of new entrants. Discussed above leads to the conclusion that threat of new entrants is medium.
The fact is that the company took a high risk. However, their decision was supported by Westphal who has co-founded five biotech companies and served as CEO of four of them all within four years. Westphal had a great track record for finding novel companies that turn basic research into drugs. This alone was enough to persuade Venture capitalists to invest in Sirtris since they repeatedly look to the reputation of the people involved as the best indicator for success. Taking the same approach as he did with his other start-ups, Westphal said that the key elements to start a company are “fantastic science… a great story… and lots of money” (Stuart, 2012). Sirtris had it all, they pushed their research further, they created a great story by emphasizing the possibilities, and they lured investor for financial support. Furthermore, the possibility that the drugs created can actually slow aging provides the company with a very compelling case to put to potential investors and pharmaceutical
Over the past years, the U.S. pharmaceutical industry R&D spending has increased at a rapid rate. Costs have been relatively stable in the preclinical phase, but have risen dramatically in the clinical phase both in terms of direct costs incurred and in time required to complete the trials.2 DiMasi reasoning for the increase in costs is from the focused development for chronic and degenerative conditions that require more costly studies for efficacy and larger clinical trial sizes.2 Some pharmaceutical companies found ways to fill their pipelines through: 1. mergers and acquisitions, 2. in-licensing new compounds, and 3. form strategic alliances and partnerships with other companies. Forming a partnership does help developing a product or drug...
Over the past decade, scientists have made significant advancements in the treatment of certain diseases. Unfortunately, just like any new product, the cost of developing these new technologies and treatments is extremely high. Plus, unlike other technology, heath technolo...
A partner to the business brings an advantage of providing additional capital, resources, and other material to develop the ABX-EGF drug program, all the while limiting the amount of risk that Abgenix takes on. For example, the drug may not develop correctly and fail in trail(s), or possibly the turns out to be unsuccessful, this after Abgenix provides a large amount of their limited resources. It’s also a benefit that the partner will have complementary knowledge, assets, and resources to market, sale, test, and develop the drug for market and/or testing. A significant hurdle is the testing phases and other regulation under the FDA Center for Drug Evaluation and Research (CDER). When the drug demonstrates its effects and the company moves forward, or makes required changes, it develops experience and knowledge that will be needed for future drug compounds. A mosaic of studies have further shown that collaboration can be a powerful tool towards higher achievement and increased productivity since collective efficacy can significantly boost groups’ aspirations, motivational investment, morale, and resilience to challenges. It’s noted that there is presence of competition in the market (AstraZeneca and Genetech), producing similar products or are in the development phase of copying the cancer fighting techniques. With that being said, adding a partner further assists Abgenix in pushing the ABX-EGF to market quicker, which decreases various costs to adapt to sudden changes. Overall, it’s in the best interest for Abgenix to join with a partner to increase the chan...
Investment opportunities all over the world are unending. There are millions of products and services that are potential game changers for the Embry Investment Group. My job as your consultant is to analyze the market and recommend the best possible investment for today and the future of the Embry Investme...
The subspecialty I plan on focusing my career around is medication therapy management (MTM), whether I work in a retail setting or not. Pharmacy informatics will be important to me, as the programs I use to fill prescriptions will also monitor the possible interactions, duplicative therapies, contraindications, etc. of the medications my patients will be receiving. This system will be my resource to ascertain which patients are in need of MTM and why, and by combining the information contained in the pharmacy’s records of the patient with information I may get from the patient’s other health care providers and the patient themselves, I will be able to see what points I need to bring up during an MTM session.
William Sharpe, Gordon J. Alexander, Jeffrey W Bailey. Investments. Prentice Hall; 6 edition, October 20, 1998
It is well known that the main idea behind any investment is capital appreciation or monetary growth. The main objective is to get rewards out of the investments in the form of profit. Wherever there is a chance of reward there is a possibility of risk.
Over the centuries, ancients made use of several treatment methods. Two of them are modern medicine and traditional medicine. Alternative medicine is older than modern one. That effective therapy has used for many centuries on the patience when modern medicine has not occurred in the world. Because it has improved in China, it can be called Traditional Chinese Medicine. In contrast, modern medicine has been in used since 1900’s. In this system, drugs’ testes are done in safety laboratories with care and nicety, and their side effects are located before they are given to the patient. However, sometimes the side effects are not blocked so, people have to take another pill to get better. It makes people to take more chemicals into their bodies. Further, modern medicine has splendid efficacy on the fatal diseases. Even, alternative medicine which people’s ancestors utilized stayed in the background when modern medicine has just found, it works at the present time efficaciously. ****** Therefore, using alternative medicine is more helpful to get better than modern medicine because there are fewer drugs, side effects; there is placebo effect and holistic therapy.
It must maximize the value of the firm, after considering amount of risk involved in the investment.
Medication non-adherence is one of factors that lead to therapy failure. There are 30% to 60% of the patients who are non-adherence to their medication and this may create a series of problems. Medication adherence mean by the extent where patients are able to follow or implement to the prescribed medication. On the other hand, the meaning of medication non-adherence is patients failed to follow the medication prescribed by health care professionals. [1]
Using the Modern Portfolio Theory, overtime risk assets will provide a higher expected rate of return, as compensation to the investors for accepting a high risk. The high risk will eventually lower collecting asset classes to the portfolio, thus reducing the volatile risk, and increasing the expected rates of return. Furthermore the purpose of this theory is to develop the most optimal investments portfolio which would yield the highest rate of return while ascertaining the risk for the individual or corporate investor.